|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
82,625,000 |
Market
Cap: |
87.58(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.04 - $4.46 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Coherus BioSciences is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of immunotherapies to treat cancer. Co. in-licensed its lead immuno-oncology product candidate, toripalimab (CHS-007), an anti-PD-1 antibody, from Shanghai Junshi Biosciences Co., Ltd. Toripalimab is being evaluated in late-stage clinical trials for the treatment of a range of tumor types. Co.'s commercial portfolio includes two U.S. Food and Drug Administration-approved biologics, including UDENYCA® (pegfilgrastim-cbqv), a biosimilar to Neulasta®, a granulocyte-colony stimulating factor and YUSIMRY (adalimumab-aqvh), its Humira® (adalimumab) biosimilar product.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
223,100 |
223,100 |
Total Sell Value |
$0 |
$0 |
$449,770 |
$449,770 |
Total People Sold |
0 |
0 |
1 |
1 |
Total Sell Transactions |
0 |
0 |
1 |
1 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Wahlstrom Mats |
Director |
|
2017-02-22 |
4 |
D |
$0.00 |
$0 |
I/I |
(200,000) |
378,528 |
|
- |
|
Viret Jean-Frederic |
Chief Financial Officer |
|
2017-01-25 |
4 |
AS |
$27.00 |
$105,300 |
D/D |
(3,900) |
2,992 |
|
- |
|
Viret Jean-Frederic |
Chief Financial Officer |
|
2017-01-25 |
4 |
OE |
$13.50 |
$52,650 |
D/D |
3,900 |
6,892 |
|
- |
|
Herman Alan C. |
Chief Scientific Officer |
|
2017-01-03 |
4 |
AS |
$27.90 |
$316,722 |
D/D |
(11,333) |
124,451 |
|
- |
|
Viret Jean-Frederic |
Chief Financial Officer |
|
2016-12-19 |
4 |
OE |
$13.50 |
$9,005 |
D/D |
667 |
2,992 |
|
- |
|
Viret Jean-Frederic |
Chief Financial Officer |
|
2016-12-16 |
4 |
AS |
$28.30 |
$110,365 |
D/D |
(3,900) |
2,325 |
|
- |
|
Viret Jean-Frederic |
Chief Financial Officer |
|
2016-12-16 |
4 |
OE |
$13.50 |
$52,650 |
D/D |
3,900 |
6,225 |
|
- |
|
Wahlstrom Mats |
Director |
|
2016-12-08 |
4 |
S |
$27.52 |
$1,271,347 |
I/I |
(46,190) |
0 |
|
- |
|
Wahlstrom Mats |
Director |
|
2016-12-07 |
4 |
S |
$27.50 |
$203,330 |
I/I |
(7,393) |
46,190 |
|
- |
|
Herman Alan C. |
Chief Scientific Officer |
|
2016-12-01 |
4 |
AS |
$27.01 |
$310,523 |
D/D |
(11,333) |
135,784 |
|
- |
|
Viret Jean-Frederic |
Chief Financial Officer |
|
2016-11-18 |
4 |
AS |
$28.19 |
$109,955 |
D/D |
(3,900) |
2,325 |
|
- |
|
Viret Jean-Frederic |
Chief Financial Officer |
|
2016-11-18 |
4 |
OE |
$13.50 |
$52,650 |
D/D |
3,900 |
6,225 |
|
- |
|
Herman Alan C. |
Chief Scientific Officer |
|
2016-11-01 |
4 |
AS |
$27.53 |
$312,042 |
D/D |
(11,333) |
147,117 |
|
- |
|
Viret Jean-Frederic |
Chief Financial Officer |
|
2016-10-21 |
4 |
AS |
$30.62 |
$119,403 |
D/D |
(3,900) |
2,325 |
|
- |
|
Viret Jean-Frederic |
Chief Financial Officer |
|
2016-10-21 |
4 |
OE |
$13.50 |
$52,650 |
D/D |
3,900 |
6,225 |
|
- |
|
Herman Alan C. |
Chief Scientific Officer |
|
2016-10-03 |
4 |
AS |
$25.47 |
$291,201 |
D/D |
(11,333) |
158,450 |
|
- |
|
Viret Jean-Frederic |
Chief Financial Officer |
|
2016-09-26 |
4 |
AS |
$29.88 |
$116,550 |
D/D |
(3,900) |
2,325 |
|
- |
|
Viret Jean-Frederic |
Chief Financial Officer |
|
2016-09-26 |
4 |
OE |
$13.50 |
$52,650 |
D/D |
3,900 |
6,225 |
|
- |
|
Lanfear Dennis M |
President and CEO |
|
2016-09-21 |
4 |
AS |
$31.75 |
$1,588 |
I/I |
(50) |
1,337,566 |
|
- |
|
Lanfear Dennis M |
President and CEO |
|
2016-09-20 |
4 |
AS |
$31.75 |
$127,322 |
I/I |
(4,010) |
1,337,616 |
|
- |
|
Lanfear Dennis M |
President and CEO |
|
2016-09-16 |
4 |
AS |
$31.79 |
$92,199 |
I/I |
(2,900) |
1,341,626 |
|
- |
|
Herman Alan C. |
Chief Scientific Officer |
|
2016-09-01 |
4 |
AS |
$29.99 |
$509,715 |
D/D |
(16,999) |
169,783 |
|
- |
|
Watler Peter K. |
Chief Technical Officer |
|
2016-08-08 |
4 |
AS |
$30.00 |
$468,649 |
I/I |
(15,621) |
0 |
|
- |
|
Watler Peter K. |
Chief Technical Officer |
|
2016-08-08 |
4 |
OE |
$2.50 |
$39,060 |
I/I |
15,621 |
15,621 |
|
- |
|
Watler Peter K. |
Chief Technical Officer |
|
2016-08-08 |
4 |
AS |
$30.00 |
$1,200,016 |
D/D |
(40,000) |
0 |
|
- |
|
312 Records found
|
|
Page 9 of 13 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|